


**Amendments To The Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (Original) A compound of formula (I)



or a salt, solvate, or physiologically functional derivative thereof, wherein:

m is an integer of from 2 to 8;

n is an integer of from 3 to 11;

with the proviso that m + n is 5 to 19;

x is zero and y is an integer of 2 or 3 or

y is zero and x is an integer of 2 or 3;


z is zero or an integer of 1 or 2;

R<sup>a</sup> and R<sup>b</sup> are independently selected from hydrogen and C<sub>1-4</sub>alkyl;


R<sup>1</sup> and R<sup>2</sup> are independently selected from hydrogen, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halo, phenyl, and C<sub>1-6</sub>haloalkyl;

R<sup>3</sup> and R<sup>4</sup> are independently selected from hydrogen and C<sub>1-4</sub>alkyl with the proviso that the total number of carbon atoms in R<sup>3</sup> and R<sup>4</sup> is not more than 4;


Ar is a group selected from



(a)




(b)



(c)

and



(d)

wherein  $R^6$  represents hydrogen, halogen,  $-(CH_2)_qOR^9$ ,  $-NR^9C(O)R^{10}$ ,  $-NR^9SO_2R^{10}$ ,  $-SO_2NR^9R^{10}$ ,  $-NR^9R^{10}$ ,  $-OC(O)R^{11}$  or  $-OC(O)NR^9R^{10}$ , and  $R^5$  represents hydrogen, halogen or  $C_{1-4}$ alkyl;

or  $R^6$  represents  $-NHR^{12}$  and  $R^5$  and  $-NHR^{12}$  together form a 5- or 6-membered heterocyclic ring;

$R^7$  represents hydrogen, halogen,  $-OR^9$  or  $-NR^9R^{10}$ ;

R<sup>8</sup> represents hydrogen, halogen, haloC<sub>1-4</sub> alkyl, -OR<sup>9</sup>, -NR<sup>9</sup>R<sup>10</sup>, -OC(O)R<sup>11</sup> or -OC(O)NR<sup>9</sup>R<sup>10</sup>;

R<sup>9</sup> and R<sup>10</sup> independently represent hydrogen or C<sub>1-4</sub> alkyl or R<sup>9</sup> and R<sup>10</sup> together with the nitrogen atom to which they are attached form a 5-, 6- or 7-membered nitrogen-containing ring,

R<sup>11</sup> represents an aryl (eg phenyl or naphthyl) group which may be unsubstituted or substituted by one or more substituents selected from halogen, C<sub>1-4</sub> alkyl, hydroxy, C<sub>1-4</sub> alkoxy or halo C<sub>1-4</sub> alkyl; and


q is zero or an integer from 1 to 4.

2. (Original) A compound according to claim 1 wherein R<sup>3</sup> and R<sup>4</sup> are independently selected from hydrogen and methyl.


3. (Currently Amended) A compound according to claim 1 ~~or claim 2~~ wherein R<sup>1</sup> and R<sup>2</sup> each represent hydrogen.

4. (Currently Amended) A compound according to claim 1 ~~any of claims 1 to 3~~ wherein the integer m is 4, 5 or 6 and n is 3, 4, 5 or 6.

5. (Currently Amended) A compound according to claim 1 ~~any of claims 1 to 4~~ wherein the group Ar is selected from groups (a) and (b).




(a)




(b)


6. (Currently Amended) A compound according to claim 5 wherein groups (a) and (b) are selected from the group consisting of following groups (i) to (xxi):




(i)




(ii)




(iii)




(iv)




(v)




(vi)




(vii)




(viii)




(ix)




(x)




(xi)




(xii)




(xiii)




(xiv)




(xv)




(xvi)




(xvii)




(xviii)



(xix)




(xx)



(xxi)

7. (Currently Amended) A compound of formula (I) according to ~~any of~~ claim 6 wherein Ar represents group (i).



8. (Currently Amended) A compound of formula (I) according to claim 1 ~~any of claims 1—7~~ wherein z represents 2.

9. (Currently Amended) A compound of formula (I) according to claim 1 which is selected from the group consisting of:

4-[(1*R*)-2-({6-[4-(1,1-Dioxido-2,3-dihydro-1-benzothien-6-yl)butoxy]hexyl}amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;  
4-[(1*r*)-2-({6-[4-(1,1-dioxido-3,4-dihydro-2*h*-thiochromen-7-yl)butoxy]hexyl}amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;

~~and~~ salts thereof, solvates thereof and physiologically functional derivatives thereof.


10. (Currently Amended) A method for the prophylaxis or treatment of a clinical condition in a mammal, ~~such as a human~~, for which a selective  $\beta_2$ -adrenoreceptor agonist is indicated, which comprises ~~administration of~~ administating a therapeutically effective amount of a compound of formula (I), according to claim 1 ~~any of claims 1—9~~, or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.

11-12. (Canceled)

13. (Currently Amended) A pharmaceutical formulation comprising a compound of formula (I), according to claim 1 ~~any of claims 1—9~~, or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.


14. (Canceled)

15. (Currently Amended) A process for the preparation of a compound of formula (I), according to claim 1 ~~any of claims 1-9~~, or a salt, solvate, or physiologically functional derivative thereof, which comprises:  
~~(a) deprotection of~~ deprotecting a protected intermediate, ~~for example of~~  
 formula (II):




or a salt or solvate thereof, wherein  $\text{R}^a$ ,  $\text{R}^b$ ,  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $m$ ,  $n$ ,  $x$ ,  $y$  and  $z$  are as defined for the compound of formula (I) or (Ia),  $\text{Ar}^1$  represents an optionally protected form of Ar; and  $\text{P}^1$  and  $\text{P}^2$  are each independently either hydrogen or a protecting group, such that the compound of formula (II) contains at least one protecting group; or

~~(b) reacting a compound of formula (IV)~~




~~wherein  $\text{Ar}^1$  is as defined above for formula (II) and  $\text{P}^1$  and  $\text{P}^2$ , each independently represent hydrogen or a protecting group, with a compound of formula (V):~~




wherein L is a leaving group such as halo or a sulfonate such as an alkylsulfonate an aryl sulfonate or a haloalkylsulfonate, and  $\text{R}^a$ ,  $\text{R}^b$ ,  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ , n, m, x, y and z are as defined for compounds of formula (I); or

(c) reacting a compound of formula (X):



wherein  $\text{Ar}^1$  and  $\text{P}^1$  are as hereinbefore defined and L is a leaving group as hereinbefore defined, with an amine of formula (XI):



wherein  $\text{R}^a$ ,  $\text{R}^b$ ,  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{P}^2$ , m, n, x, y and z are as defined for formula (II);

followed by removal of any protecting groups;


wherein said deprotecting step is optionally followed by one or more of the following steps in any order selected from the group consisting of:

- (i) optional removal of removing any protecting groups;
- (ii) optional separation of separating an enantiomer from a mixture of enantiomers;




- (iii) ~~optional conversion of~~ converting one compound of formula (I) to a different compound of formula (I); and
- (iv) ~~optional conversion of~~ converting the product to a corresponding salt, solvate, or physiologically functional derivative thereof.

16. (New) A process for the preparation of a compound of formula (I), according to claim 1, or a salt, solvate, or physiologically functional derivative thereof, which comprises reacting a compound of formula (IV):



wherein  $\text{Ar}^1$  represents an optionally protected form of Ar; and  $\text{P}^1$  and  $\text{P}^2$  each independently represent hydrogen or a protecting group, with a compound of formula (V):




wherein L is a leaving group, and  $\text{R}^a$ ,  $\text{R}^b$ ,  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ , n, m, x, y and z are as defined for compounds of formula (I);

wherein said reacting step is optionally followed by one or more of the following steps in any order selected from the group consisting of:


- (i) removing any protecting groups;
- (ii) separating an enantiomer from a mixture of enantiomers;

- (iii) converting one compound of formula (I) to a different compound of formula (I); and
- (iv) converting the product to a corresponding salt, solvate, or physiologically functional derivative thereof.

17. (New) A process for the preparation of a compound of formula (I), according to claim 1, or a salt, solvate, or physiologically functional derivative thereof, which comprises reacting a compound of formula (X):



wherein  $\text{Ar}^1$  represents an optionally protected form of Ar;  $\text{P}^1$  independently represents hydrogen or a protecting group and L is a leaving group, with an amine of formula (XI):



wherein  $\text{R}^a$ ,  $\text{R}^b$ ,  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ , m, n, x, y and z are as defined; and  $\text{P}^2$  represents hydrogen or a protecting group;

wherein said reacting step is optionally followed by one or more of the following steps in any order selected from the group consisting of:

- (i) removing any protecting groups;
- (ii) separating an enantiomer from a mixture of enantiomers;
- (iii) converting one compound of formula (I) to a different compound of formula (I); and
- (iv) converting the product to a corresponding salt, solvate, or physiologically functional derivative thereof.

18. (New) The method according to claim 10, wherein the mammal is a human.

19. (New) The process according to Claim 16, wherein L is a halo or sulfonate leaving group.

20. (New) The process according to Claim 19, wherein L is selected from the group consisting of an alkylsulfonate, an aryl sulfonate, and a haloalkylsulfonate.

21. (New) The process according to Claim 17, wherein L is a halo or sulfonate leaving group.

22. (New) The process according to Claim 21, wherein L is selected from the group consisting of an alkylsulfonate, an aryl sulfonate, and a haloalkylsulfonate.